chen, chenyan – page 3 – eisai china lnc.-乐鱼官方网站在线登录入口

 chen, chenyan – page 3 – eisai china lnc.-乐鱼官方网站在线登录入口

entries by

sahne medical spray is the first otc drug spray-type lotion containing heparinoid

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has launched sahne® medical spray and sahne® medical cream (both are category-2 otc drugs, “sahne medical”) on august 25, 2020 at pharmacies and drugstores throughout japan, as a new product of the sahne brand lineup which has been a favored hand care for generations.

eisai to present latest data of lemborexant at 34th annual sleep meeting (sleep2020)

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: dayvigotm civ) will be given at the 34th annual meeting of the associated professional sleep societies (sleep 2020), to be held virtually from august 27 to 30, 2020.

application for additional indication of anti cancer agent lenvima® for unresectable thymic carcinoma submitted in japan

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and msd k.k. (headquarters: tokyo, president: jannie oothuizen, “msd”), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., announced today that eisai has submitted an application in japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor lenvima ® (generic name: lenvatinib mesylate). in june 2020, lenvima received orphan drug designation in japan for unresectable thymic carcinoma.

eisai and dena to provide smartphone app “easiit app” through business alliance agreement

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and dena co., ltd.’s subsidiary desc healthcare co., ltd. (headquarters: tokyo, ceo: sho segawa, cmo: kuniaki miyake, “dena”) announced that they have begun provision of the brain performance application “easiit” (non-medical device, referred to below as “easiit app”), for preparation against dementia, on july 28, 2020.

allm inc. (shibuya-ku, tokyo, president: teppei sakano, hereafter allm), tokyo medical and dental university (bunkyo-ku, tokyo, president: yujiro tanaka) and eisai co., ltd. (headquarters: bunkyo-ku, tokyo, ceo: haruo naito, hereafter eisai) announced that their jointly submitted study and development project has been selected by the japan agency for medical research and development (amed) for its publicly advertised 2020 “field of support for experimental study on medical devices and systems that contribute to measures against viruses and other infectious diseases” as part of its “technology development project for measures against viruses and other infectious diseases “, and that allm has entered into an industry-academia-government joint research agreement with tokyo medical and dental university and eisai respectively.

initiation of new phase iii clinical study (ahead 3-45) of ban2401 preclinical (asymptomatic) alzheimer’s disease

the alzheimer’s clinical trials consortium (actc), eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”), and biogen inc. (nasdaq: biib, headquarters: cambridge, massachusetts, united states, ceo: michel vounatsos, “biogen”) announced today that a new phase iii clinical study (ahead 3-45) of ban2401, an anti-amyloid beta (aβ) protofibril antibody, has been initiated in the united states of america for individuals with preclinical alzheimer’s disease (ad), meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into an industry-academia-government joint research agreement with four universities in japan concerning the “industrialization of japan-originated toll-like receptor research by academia-industry collaborating all-japan system: creation of new drug for sle treatment”, which is a research project with eisai as the representative research organization. this joint research project was selected by the japan agency for medical research and development (amed) for its cyclic innovation for clinical empowerment (cicle) grant program. in this project, eisai aims at creating a japan-originated therapeutic drug for systemic lupus erythematosus (sle) through industry-academia-government collaboration, using its in-house discovered new oral toll-like receptor (tlr) 7/8 inhibitor e6742.

new fine granule formulation of anti-epileptic drug fycompa® launched in japan

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (aed) fycompa® (perampanel hydrate) in japan on july 6, 2020. eisai received marketing and manufacturing approval for this formulation on january 23, 2020, and the fine granule formulation was added to japan’s national health insurance drug price list on april 23 of the same year.

eisai receives approval for parkinson’s disease treatment equfina® in south korea

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that eisai korea inc., eisai’s subsidiary in south korea, has received marketing approval of parkinson’s disease treatment equfina® (safinamide mesilate, “safinamide”) for the indication of treatment of idiopathic parkinson’s disease as adjunctive therapy with levodopa-containing products in patients with end of dose motor fluctuations from the regulatory authority in south korea (ministry of food and drug safety).

网站地图